PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q3 2015 13F Holders as of 30 Sep 2015

Type / Class
Equity / COM
Total 13F shares
67,404,510
Share change
+366,018
Total reported value
$385,527,362
Put/Call ratio
153%
Price per share
$5.72
Number of holders
130
Value change
+$1,107,264
Number of buys
65
Number of sells
54

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q3 2015

As of 30 Sep 2015, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 130 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 67,404,510 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, Broadfin Capital, LLC, FMR LLC, STATE STREET CORP, BAKER BROS. ADVISORS LP, ROYCE & ASSOCIATES LLC, BlackRock Fund Advisors, TUDOR INVESTMENT CORP ET AL, VANGUARD GROUP INC, and MILLENNIUM MANAGEMENT LLC. This page lists 130 institutional shareholders reporting positions in this security for the Q3 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.